| Literature DB >> 26205308 |
Daniele Vergara1,2, Michele D'Alessandro3, Antonia Rizzello4,5, Lidia De Riccardis6, Paola Lunetti7, Piero Del Boccio8, Francesca De Robertis9, Giorgio Trianni10, Michele Maffia11,12, Anna M Giudetti13.
Abstract
BACKGROUND: Lipids play different important roles in central nervous system so that dysregulation of lipid pathways has been implicated in a growing number of neurodegenerative disorders including multiple sclerosis (MS). MS is the most prevalent autoimmune disorder of the central nervous system, with neurological symptoms caused by inflammation and demyelination. In this study, a lipidomic analysis was performed for the rapid profile of CD4(+) T lymphocytes from MS patient and control samples in an untargeted approach.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26205308 PMCID: PMC4513631 DOI: 10.1186/s12868-015-0183-1
Source DB: PubMed Journal: BMC Neurosci ISSN: 1471-2202 Impact factor: 3.288
Clinical characteristics for the multiple sclerosis (MS) and healthy control (HC) groups
| No. | Sex | Age (years) | Diagnosis/classification | EDSS |
|---|---|---|---|---|
| MS1 | M | 35 | RRMS | 1.5 |
| MS2 | F | 32 | RRMS | 3.5 |
| MS3 | F | 27 | RRMS | 2.5 |
| MS4 | F | 18 | RRMS | 3.0 |
| MS5 | F | 35 | RRMS | 1.7 |
| MS6 | F | 24 | RRMS | 3.9 |
| MS7 | M | 35 | RRMS | 2.0 |
| MS8 | M | 40 | RRMS | 2.3 |
| HC1 | M | 37 | Healthy control | na |
| HC2 | F | 28 | Healthy control | na |
| HC3 | F | 30 | Healthy control | na |
| HC4 | M | 48 | Healthy control | na |
| HC5 | F | 32 | Healthy control | na |
RRMS relapsing remitting MS, EDSS Expanded Disability Status Scale, na not applicable.
Figure 1MALDI-TOF mass spectra of lipids from CD4+ T lymphocytes obtained in positive and negative mode. Representative MALDI-TOF mass spectra of lipids extracted from CD4+ T lymphocytes (upper panels) prepared by the Bligh and Dyer procedure. Spectra were acquired in both negative (a) and positive (b) mode, using the 9-AA matrix by averaging 2.000 consecutive laser shots. MALDI-TOF spectra of 9-AA matrix detected in negative (c) and positive mode (d) is reported. Spectra were acquired using a Ultraflex Extreme MALDI-TOF/TOF (Bruker).
Figure 2MALDI-TOF mass spectra of CD4+ lipids from MS and control subjects obtained in negative mode. Representative negative ion MALDI-TOF spectrum of total lipid extracts from healthy controls (a) and multiple sclerosis patients (b) CD4+ T lymphocytes, using the 9-AA matrix by averaging 2.000 consecutive laser shots.
Assignment based on m/z measurements of peaks detected in the negative ion mass spectra of lipids from CD4+ T lymphocytes using 9-AA as matrix
|
| Assignment [M-H]− |
| Assignment [M-H]− |
|---|---|---|---|
| 513,400 | Matrix | 799,767 | SM d17:1/24:0 or d18:1/23:0 |
| 529,389 | Matrix | 800,596 | PE 41:0 or PS 37:2 |
| 573,412 | Matrix | 802,607 | PE 42:6 or PS 38:1 |
| 617,430 | Matrix | 806,584 | PE 42:4 |
| 618,557 | Matrix | 808,601 | PE 41:4 or PS 38:5 |
| 619,371 | PA 30:0 | 826,604 | PE 42:2 |
| 666,141 | Matrix | 828,631 | PE 42:1 |
| 687,632 | DG 41:3 | 836,632 | PE 43.4 or PS 40:5 |
| 722,603 | PE 36:4 | 850,617 | PE 44:4 or PS 42:4 |
| 738,599 | Sphyngolipid 15:2/22:0 | 852,631 | PE 44:3 |
| 742,634 | PE 36:2 | 857,625 | PG 42:2 |
| 743,696 | SM 37:1 | 859,642 | PI 36:2 |
| 744,652 | PE 36:1 | 861,640 | PG 42:0 or PI 36:2 |
| 746,600 | PE 36:0 | 883,642 | PI 38:5 |
| 750,636 | Sphyngolipid 18:2/20:1 | 885,661 | PG 44:2 |
| 760,934 | PE O-38:0 | 901,657 | PI 40:2 |
| 764,619 | PE 38:5 | 909,663 | PI 40:6 |
| 766,634 | Sphyngolipid 18:2/21:0 | 911,618 | PI 40:6 |
| 769,716 | PA 42:1 or SM 39:0 | 913,696 | PI 40:4 |
| 771,732 | PA 42:0 or SM 38:1 | 943,623 | PI 42:3 |
| 776,849 | PE O-40:6 or PS O-36:0 | 1.448,140 | CL 72:8 |
| 778,651 | PE 40:4 | 1.470,150 | CL 74:11 |
| 780,560 | PE 41:4 | 1.472,170 | CL 74:10 |
| 782,562 | PE 41:3 | 1.494,150 | CL 75:6 |
| 792,650 | PE 40:5 | 1.496,170 | CL 75:5 |
| 794,675 | Sphingolipid 18:2/23:0 | 1.498,190 | CL 75:4 |
| 795,736 | PI O-32:0 | ||
| 797,754 | SM d17/24:1 |
For the identification, mass tolerance was set to ±0.1.
CL cardiolipin, DG diacylglycerol, PA phosphatic acid, PE phosphatidylethanolamine, PS phosphatidylserine, PI phosphatidylinositol, PG phosphatidylglycerol, SM sphingomyelin.
Figure 3Partial least squares discriminat analysis. Partial least squares discriminat analysis (PLS-DA) score plot from lipidomics data derived from control (black triangle) and MS (red circle) patients. Below, histograms show peaks that were significantly different (P < 0.05) among groups. Data reported as mean ± SD.
Metabolites whcich allowed the separation between healthy and multiple sclerosis patients selected on the the basis of VIP
|
| Regulation in MS | P value | Ion | Lipid species |
|---|---|---|---|---|
| 861,640 | Up-regulated | 0.037 | [M-H]− | PG 42:0 or PI 36:2 |
| 911,618 | Up-regulated | 0.042 | [M-H]− | PI 40:5 |
| 1.448,140 | Up-regulated | 0.042 | [M-H]− | CL 72:8 |
| 1.472,170 | Up-regulated | 0.047 | [M-H]− | CL 74:10 |
A P value <0.05 was set as the threshold to define significant differences.
Figure 4MS/MS based characterization of the cardiolipin m/z 1,448,14 ion. Representative MS spectra of cardiolipin species obtained from a MS sample (a), and from cardiolipin standard (b). Following MS/MS of the 1,448,14 cardiolipin generated fragment ions were illustrated (c); cardiolipin structure is reported in the insert.
Fatty acid composition of CD4+ T lymphocytes
| Fatty acids | HC | MS |
|---|---|---|
| 14:0 | 1.5 ± 0.6 | 1.9 ± 0.7 |
| 16:0 | 34.3 ± 1.2 | 31.8 ± 2.0 |
| 16:1 | 0.2 ± 0.08 | 0.3 ± 0.09 |
| 18:0 | 57.2 ± 1.2 | 54.2 ± 4.0 |
| 18:1n-9 | 3.1 ± 0.5 | 5.6 ± 1.7* |
| 18:1n-11 | 0.7 ± 0.06 | 0.9 ± 0.08** |
| 18:2n-6 | 1.4 ± 0.2 | 2.0 ± 0.7 |
| 18:3n-3 | 0.5 ± 0.03 | 0.3 ± 0.01** |
| 20:4n-6 | 1.5 ± 0.1 | 4.4 ± 0.2** |
| Σ SFA | 92.9 ± 0.6 | 86.9 ± 4.3*** |
| Σ MUFA | 3.3 ± 0.2 | 5.8 ± 1.7*** |
| Σ PUFA | 3.3 ± 0.4 | 6.7 ± 0.9** |
| Total n-6 | 2.8 ± 0.9 | 6.4 ± 0.3** |
| SFA/PUFA | 14.4 ± 1.7 | 7.9 ± 3.8*** |
| UI | 13.7 ± 3.2 | 29.1 ± 11.6*** |
Fatty acids were obtained from whole CD4+ T lymphocytes as reported in the “Methods” section. Values are expressed as percentage of total fatty acids.
MUFA monounsaturated fatty acids, PUFA polyunsaturated fatty acids, SFA saturated fatty acids, UI Unsaturation index.
Values are given as mean ± SD.
* P < 0.05; ** P < 0.01; *** P < 0.001.